June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The role of systemic infection and response to Ranibizumab therapy for Age Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • Charles Pierce
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
    University Hospital of Southampton, Southampton, United Kingdom
  • Marie Nelson
    University Hospital of Southampton, Southampton, United Kingdom
  • Jennifer Scott
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
  • Helen Griffiths
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
  • Natalee James
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
  • Heather Thomson
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
  • Angela Cree
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
  • Andrew Lotery
    Clinical Neurosciences, University of Southampton, Southampton, United Kingdom
    University Hospital of Southampton, Southampton, United Kingdom
  • Footnotes
    Commercial Relationships Charles Pierce, Genentech (F); Marie Nelson, None; Jennifer Scott, None; Helen Griffiths, None; Natalee James, None; Heather Thomson, None; Angela Cree, None; Andrew Lotery, Novartis (F), Bayer (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4105. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Charles Pierce, Marie Nelson, Jennifer Scott, Helen Griffiths, Natalee James, Heather Thomson, Angela Cree, Andrew Lotery, ; The role of systemic infection and response to Ranibizumab therapy for Age Related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2013;54(15):4105.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

In the chronic neurodegenerative disease, Alzheimer’s disease, systemic inflammation has been associated with progression and relapse of the disease. Chronic and acute inflammation has also been implicated in choroidal angiogenesis and subsequent AMD development. We hypothesised that system inflammation may also alter the response of AMD to the anti-vascular endothelial growth factor (VEGF) agent Ranibizumab.

 
Methods
 

Patients attending the Southampton Eye Unit (SEU) for treatment of AMD with Ranibizumab were enrolled at their third loading intravitreal injection. Patients were seen monthly at their clinical review. Systemic illness, further anti-VEGF injections or changes to medication were noted. Each patient was enrolled for 6 months. Demographic information was obtained from casenotes and patient questionnaires. Recorded optical coherence tomography (OCT) scans provided objective evidence of CNV activity.

 
Results
 

Our initial demographic analysis did not show a relationship between administered Ranibizumab intravitreal injections and recorded systemic infections (p= 0.863). There was also no relationship between central macular thickness (CMT) change from baseline and patient reported systemic infection (p=0.270).

 
Conclusions
 

This analysis of demographic data showed no relationship between patient reported systemic infections and CMT. Further study of inflammatory cytokines may provide more direct / alternative evidence of the effect of systemic inflammation on CNV activation.

 
 
Mean change in CMT from baseline
 
Mean change in CMT from baseline
   
Keywords: 412 age-related macular degeneration • 557 inflammation • 464 clinical (human) or epidemiologic studies: risk factor assessment  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×